What a New Tau Study Tells Us About Dementia Tests

Two women sit at a kitchen table reviewing a sheet of paper together.

Date

Words like “tau” can make a blood-test headline sound more definitive than it is. A new study in JAMA found that one experimental tau marker, long studied in Alzheimer’s disease, also rose in small groups with two other kinds of brain disease. The finding matters because it clarifies what a test might be picking up. It does not give families a new test to request.

What the researchers looked for

Tau is a protein found in brain cells. It can build up abnormally in Alzheimer’s disease and in several other conditions, but the form of tau involved is not always the same. The researchers measured a small piece of the protein called eMTBR-tau243. They wanted to know whether higher levels point only to Alzheimer’s or also show up in other diseases where two forms of tau accumulate together.

The study was published online November 13, 2026. It compared samples from 229 participants across four U.S. research banks. The laboratory work took place between August 2023 and December 2025. Most participants contributed fluid from around the brain and spinal cord, and only 55 had blood samples in the study. About half had samples that could be compared with findings from a brain examination after death or with genetic evidence about the type of tau disease.

Where the marker showed up

In the studyWhat families should know
Alzheimer’s disease: Levels were higher in the sampled groups than in people without cognitive impairment.This marker was not unique to Alzheimer’s. A higher level on this experimental assay is not a diagnosis.
Chronic traumatic encephalopathy (CTE): The blood marker separated a small group with more advanced CTE from people without cognitive impairment, but it did not show a clear distinction between the earliest-stage cases and that comparison group.That comparison does not establish a clinically validated blood test for CTE or show that it can tell CTE from other causes of symptoms.
Inherited frontotemporal degeneration: The marker in spinal fluid was elevated in a small subset with particular variants in the gene that makes tau.The finding does not apply to all frontotemporal dementia or even all variants in that gene. It does not replace a clinical or genetic evaluation.

Source: Horie and colleagues, JAMA.

A research clue, not a new test for your loved one

This was a comparison of selected research samples, not a trial of how the test performs when someone comes to a clinic with unexplained changes. The groups were small and came from different research banks. For example, the CTE blood comparison included 11 participants with CTE and 20 without cognitive impairment. Some authors disclosed patents or financial ties related to biomarker development. Larger, independent studies would need to show whether this measurement helps a clinician sort through overlapping conditions in real-world care.

It is also not the same test as the blood test the FDA first cleared in 2025 to help evaluate Alzheimer’s in certain adults with symptoms. That test measures a different tau marker alongside an amyloid marker. The FDA’s announcement explains that even that cleared test is not intended for screening or for making a diagnosis on its own.

If biomarker testing comes up at an appointment, a useful question is: “What would this specific test tell us, and what would we still need to find out?” That keeps the conversation focused on what the result would mean for your loved one, rather than what a headline seems to promise.

Related reading: recent FTD research on everyday support needs and our earlier coverage of different Alzheimer’s blood markers.

This article is for general education and is not a substitute for individualized medical advice.

Picture of Marcelo Oleas

Marcelo Oleas

Marcelo is the founder of DementiaHelp.io and a dedicated advocate for dementia caregivers. After spending over six years as a caregiver helping three family members navigating Frontotemporal Dementia, Lewy Body, and Alzheimer’s, he created this platform to share the practical resources and emotional support he found lacking during his own journey. Marcelo is also the President of M4 Worldwide, Inc., and a life coach specializing in helping others to nurture self-love in their personal growth journey.

** Ad Disclaimer: As an Amazon Associate, we earn from qualifying purchases. **

More
articles